Clinical Trial Update: Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

View source ↗

Summary

Phase 4 trial update evaluating whether AdreView scintigraphy using iobenguane can prognosticate mortality risk in heart failure patients over a 60-month follow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• ADREVIEW (IOBENGUANE I-123)

Snippet

Sponsor: GE Healthcare | Conditions: Heart Failure (HF) | Status: COMPLETED | Results posted: 2017-03-28